Abdul Ahad Ahsan, Member – Research Division at MedNews Week, shared on LinkedIn:
“Evolving Treatment Paradigms in Muscle-Invasive Bladder Cancer.
What’s next for muscle-invasive bladder cancer treatment?
In this Medical Spotlight by MedNews Week × OncoDaily, Dr. Karine Tawagi shares her insights into precision oncology, immunotherapy, clinical trials, and real-world evidence-and how these advances can translate into more accessible, equitable, and patient-centered cancer care.
Beyond the science, Dr. Tawagi reflects on her own journey through medical oncology, clinical research, education, and leadership, offering a perspective on how clinicians can contribute to shaping the future of cancer care.
Watch NOW on YouTube OncoDaily TV.”
To which, Ayesha Junaid, Final-Year MBBS Student at Dow Medical College, added:
“When a field is changing this quickly, perhaps the hardest question is no longer
‘What works?’,
but
‘Where does each new advance actually belong?’
Muscle-invasive bladder cancer is entering an incredibly interesting era, and this conversation with Dr. Karine Tawagi captures exactly why.
From the Niagara paradigm and peri-operative chemo-immunotherapy to EV/pembrolizumab, ctDNA-guided decision-making and surveillance, the discussion explores some of the questions clinicians are now having to navigate as new evidence reshapes the treatment landscape.
What made the conversation even more valuable was that it didn’t stop at the science. Dr. Tawagi also brings attention to access, implementation, medical education, mentorship, and training the next generation of oncologists, all of which ultimately determine how advances in oncology translate beyond clinical trials.
A conversation full of questions that don’t necessarily have simple answers yet and that is exactly what makes it worth watching. Grateful for the opportunity to learn from Dr. Tawagi’s perspective.”
You can also read ‘Yan Leyfman: Discussion on Evolving Treatment Paradigms in Muscle-Invasive Bladder Cancer‘
